Supernus Pharmaceuticals (SUPN) Share-based Compensation (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Share-based Compensation data on file, last reported at $8.5 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $8.5 million, up 5.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.5 million (up 11.82% YoY), and the FY2025 annual result was $33.1 million, up 19.08% from the prior year.
• Share-based Compensation eased to $8.5 million in Q1 2026 per SUPN's latest filing, from $9.7 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $9.7 million in Q4 2025 and troughed at $4.0 million in Q1 2022.
• A 5-year average of $6.7 million and a median of $6.6 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation dropped 21.53% in 2022, then surged 58.88% in 2023.
• A 5-year view of Share-based Compensation shows it stood at $4.3 million in 2022, then jumped by 51.26% to $6.4 million in 2023, then gained by 18.42% to $7.6 million in 2024, then increased by 26.45% to $9.7 million in 2025, then fell by 12.13% to $8.5 million in 2026.
• Business Quant data shows SUPN's Share-based Compensation at $8.5 million in Q1 2026, $9.7 million in Q4 2025, and $7.8 million in Q3 2025.